About us

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

  • Merck

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Pfizer Eastern Europe

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Alcon

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Community Foundation

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

become our partner

Improving the lives of patients
by developing proprietary, innovative

Dr n. o zdr. Piotr Hirnle, MSc

udziałowiec, Członek Zarządu, Dyrektor Finansowy, Dyrektor B+R

Ponad 15 lat doświadczenia w doradztwie i zarządzaniu projektami badawczo-rozwojowymi, koordynator ponad 50 badań klinicznych i przedklinicznych. Zastępca Dyrektora ds. Administracji, Finansów i Zarządzania Projektami B+R w Centrum Badawczo-Rozwojowym American Heart of Poland (uprzednio). Absolwent Szkoły Głównej Handlowej, posiada stopień doktora nauk o zdrowiu, a także dyplom Master of Science przyznany przez London School of Economics and Political Science.